Last 12 months
Inside the activity.
2 purchase rows · 107 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 26 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 9 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2023 Filed May 11, 2023 23:30 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 30,000 | $23.87 | $716,100.00 |
DisclosureSEC source: 0000899243-23-012758 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,997 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.81 to $24.04. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 08, 2023 Filed May 9, 2023 20:45 UTC |
MAHONEY DAVID LDirector
|
Exercise / conversionStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0000899243-23-012472 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2023-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 08, 2023 Filed May 9, 2023 20:45 UTC |
MAHONEY DAVID LDirector
|
Tax withholdingCommon Stock | 2,197 | $23.76 | $52,200.72 |
DisclosureSEC source: 0000899243-23-012472 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,237,078 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on May 8, 2023. The options subject to the net exercise were to expire on May 17, 2023. F2 · balance_after: Fully exercisable. Read SEC document |
| May 08, 2023 Filed May 9, 2023 20:45 UTC |
MAHONEY DAVID LDirector
|
Exercise / conversionCommon Stock | 30,000 | $1.74 | $52,200.00 |
DisclosureSEC source: 0000899243-23-012472 · doc4.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,239,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Fully exercisable. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,963 Underlying: Common Stock · 60,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 7 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2023-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Robb Gary CharlesChief Business Officer
|
Tax withholdingCommon Stock | 60,586 | $24.07 | $1,458,305.02 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,997 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on May 5, 2023. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionCommon Stock | 60,000 | $3.29 | $197,400.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:45 UTC |
Robb Gary CharlesChief Business Officer
|
Exercise / conversionCommon Stock | 45,000 | $1.92 | $86,400.00 |
DisclosureSEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007055 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,382 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC |
Maduck SeanSee Remarks
|
GrantCommon Stock | 1,460 | $19.86 | $28,995.60 |
DisclosureSEC source: 0000899243-23-007055 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,922 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007054 · doc4.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,106 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC |
Mokari AtabakChief Financial Officer
|
GrantCommon Stock | 1,260 | $19.86 | $25,023.60 |
DisclosureSEC source: 0000899243-23-007054 · doc4.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,846 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:53 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,583 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:53 UTC |
Robb Gary CharlesChief Business Officer
|
GrantCommon Stock | 1,600 | $19.86 | $31,776.00 |
DisclosureSEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,983 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:52 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 1,472 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007051 · doc4.xml · nonDerivative · entry 2 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,788 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:52 UTC |
Guyer WilliamChief Development Officer
|
GrantCommon Stock | 1,472 | $19.86 | $29,233.92 |
DisclosureSEC source: 0000899243-23-007051 · doc4.xml · nonDerivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,316 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:50 UTC |
Lyon Joseph DouglasChief Accounting Officer
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007049 · doc4.xml · nonDerivative · entry 2 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,310 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:50 UTC |
Lyon Joseph DouglasChief Accounting Officer
|
GrantCommon Stock | 1,155 | $19.86 | $22,938.30 |
DisclosureSEC source: 0000899243-23-007049 · doc4.xml · nonDerivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| March 01, 2023 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
OtherCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 12 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 56,976 F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust. F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Read SEC document |
| March 01, 2023 Filed Jun 3, 2025 00:57 UTC |
Maduck SeanSee Remarks
|
GiftCommon Stock | 1,460 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 11 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,646 F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 22, 2023 Filed Feb 13, 2024 01:12 UTC |
Robb Gary CharlesChief Business Officer
|
GiftCommon Stock | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014085 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,465 F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 01:02 UTC |
Guyer WilliamChief Development Officer
|
GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005179 · doc4.xml · derivative · entry 1 Guyer William · CIK 0001879013 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 01:01 UTC |
Lyon Joseph DouglasChief Accounting Officer
|
GrantStock option (right to buy) · Derivative | 120,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005177 · doc4.xml · derivative · entry 1 Lyon Joseph Douglas · CIK 0001817838 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC |
Mokari AtabakChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005174 · doc4.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 01:00 UTC |
Hunt HazelChief Scientific Officer
|
GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005176 · doc4.xml · derivative · entry 1 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
GrantStock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005173 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC |
Robb Gary CharlesChief Business Officer
|
GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000950170-23-002950 · ownership.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:58 UTC |
Maduck SeanSee Remarks
|
GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005172 · doc4.xml · derivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| January 01, 2023 Filed Feb 13, 2024 21:46 UTC |
BAKER G LEONARD JRDirector
|
GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003184 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By limited partnership Disclosed balance after: 3,308,303 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| December 16, 2022 Filed Feb 15, 2023 00:30 UTC |
MAHONEY DAVID LDirector
|
GiftCommon Stock | 21,297 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005067 · doc5.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,209,275 F1 · balance_after: This total includes 24,214 shares disclosed as being directly owned by the Reporting Person in a Form 4 filed on May 31, 2022. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC |
Robb Gary CharlesChief Business Officer
|
GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 11 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC |
Robb Gary CharlesChief Business Officer
|
GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 10 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| December 15, 2022 Filed Feb 15, 2023 00:30 UTC |
Robb Gary CharlesChief Business Officer
|
GiftCommon Stock | 772 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 9 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Custodial account for child Disclosed balance after: 7,336 F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian. Read SEC document |
| December 13, 2022 Filed Feb 15, 2023 00:30 UTC |
MAHONEY DAVID LDirector
|
GiftCommon Stock | 26,030 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005067 · doc5.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,230,572 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 625 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,977 Underlying: Common Stock · 625 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 625 | $25.28 | $15,800.00 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 625 | $3.29 | $2,056.25 |
DisclosureSEC source: 0000899243-22-037636 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 23, 2022 Filed Nov 23, 2022 23:30 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 186 | $26.03 | $4,841.58 |
DisclosureSEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,143 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 23:30 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 4,814 | $26.03 | $125,308.42 |
DisclosureSEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,329 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 21, 2022 Filed Feb 15, 2023 00:30 UTC |
Robb Gary CharlesChief Business Officer
|
GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 8 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,383 Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 22:15 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 13,401 | $26.43 | $354,188.43 |
DisclosureSEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,143 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 22:15 UTC |
Robb Gary CharlesChief Business Officer
|
SaleCommon Stock | 10,000 | $26.06 | $260,600.00 |
DisclosureSEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,544 F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 25,000 | $25.57 | $639,250.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.55 to $25.65. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:45 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-035882 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · derivative · entry 5 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,602 Underlying: Common Stock · 25,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC |
Maduck SeanSee Remarks
|
SaleCommon Stock | 25,000 | $25.64 | $641,000.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · nonDerivative · entry 2 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,462 F1 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.64 to $25.66. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 21:30 UTC |
Maduck SeanSee Remarks
|
Exercise / conversionCommon Stock | 25,000 | $3.29 | $82,250.00 |
DisclosureSEC source: 0000899243-22-032731 · doc4.xml · nonDerivative · entry 1 Maduck Sean · CIK 0001698310 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC |
Hunt HazelChief Scientific Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0000899243-22-032305 · doc4.xml · derivative · entry 3 Hunt Hazel · CIK 0001698307 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.